BioRestorative Therapies, Inc. (BRTX) SEC filings

BRTXNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31

Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 14, 2026Score 8/30

$1.49−0.01 (-0.67%)

Close on Nov 13, 2026Market cap $37.96MP/E –Yield –

SEC filings

40 of BioRestorative Therapies's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Nov 5, 2026	Nov 12, 2026	SEC EDGAR
Current report	8-K	Oct 7, 2026	Oct 9, 2026	SEC EDGAR
Current report	8-K	Sep 4, 2026	Sep 11, 2026	SEC EDGAR
Current report	8-K	Sep 2, 2026	Sep 2, 2026	SEC EDGAR
Current report	8-K	Aug 26, 2026	Sep 2, 2026	SEC EDGAR
Current report	8-K	Aug 21, 2026	Aug 25, 2026	SEC EDGAR
Current report	8-K	Aug 7, 2026	Aug 14, 2026	SEC EDGAR
Current report	8-K	Jul 8, 2026	Jul 16, 2026	SEC EDGAR
Current report	8-K	Jun 10, 2026	Jun 12, 2026	SEC EDGAR
Current report	8-K	Jun 10, 2026	Jun 12, 2026	SEC EDGAR
Current report	8-K	May 26, 2026	May 29, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 14, 2026	SEC EDGAR
Current report	8-K	May 1, 2026	May 1, 2026	SEC EDGAR
Current report	8-K	Apr 23, 2026	Apr 23, 2026	SEC EDGAR
Proxy statement	DEF 14A	May 26, 2026	Apr 13, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 26, 2026	SEC EDGAR
Current report	8-K	Feb 11, 2026	Feb 17, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 12, 2025	SEC EDGAR
Current report	8-K	Nov 12, 2025	Nov 12, 2025	SEC EDGAR
Current report	8-K	Oct 6, 2025	Oct 8, 2025	SEC EDGAR
Current report	8-K	Sep 18, 2025	Sep 25, 2025	SEC EDGAR
Current report	8-K	Aug 14, 2025	Aug 14, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 12, 2025	SEC EDGAR
Current report	8-K	Aug 12, 2025	Aug 12, 2025	SEC EDGAR
Proxy statement	DEF 14A	Aug 8, 2025	Aug 8, 2025	SEC EDGAR
Current report	8-K	Jun 13, 2025	Jun 13, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 14, 2025	SEC EDGAR
Current report	8-K	May 14, 2025	May 14, 2025	SEC EDGAR
Current report	8-K	Apr 16, 2025	Apr 21, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 28, 2025	SEC EDGAR
Current report	8-K	Mar 27, 2025	Mar 27, 2025	SEC EDGAR
Current report	8-K	Feb 10, 2025	Feb 10, 2025	SEC EDGAR
Current report	8-K	Nov 12, 2024	Nov 13, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 12, 2024	SEC EDGAR
Current report	8-K	Nov 6, 2024	Nov 7, 2024	SEC EDGAR
Annual report, amended	10-K/A	Dec 31, 2023	Nov 6, 2024	SEC EDGAR
Current report	8-K	Nov 1, 2024	Nov 6, 2024	SEC EDGAR
Current report	8-K	Sep 19, 2024	Sep 23, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 13, 2024	SEC EDGAR
Current report	8-K	Aug 13, 2024	Aug 13, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in BioRestorative Therapies's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-20 reverse split on Sep 8, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BRTX.

Compare: BRTX vs MGRX · BRTX vs BICX · BRTX vs YDES · BRTX vs ARTV · BRTX vs ERNA

Company	Revenue	Growth
BRTX	$357.87K	-8.5%
MGRX	$315.23K	-38.9%
BICX	–	–
YDES	–	–
ARTV	–	–
ERNA	–	–

Company

Exchange: Nasdaq
Industry: Services-Misc Health & Allied Services, NEC
Fiscal year ends: December 31
Employees: 14
Held by institutions: 0.5%
Auditor: Marcum LLP
SEC CIK: 1505497

Advertisement
300 × 250

See a number that looks wrong?